EagleDream Health announced in October that they have entered into an exclusive partnership with Medline for the marketing and distribution of their software and services.

As discussed earlier, EagleDream Health offers a sophisticated analytical tool that allows healthcare providers, networks, and insurers to monitor and to understand how individual clinical decisions impact not only patient outcomes, but also the overall performance of their entire operation.

Medline is a global manufacturer and distributor serving the healthcare industry with medical supplies and clinical solutions that help their customers achieve both clinical and financial success.

This partnership allows EagleDream Health to benefit from Medline’s vast experience and customer network, while giving Medline the exclusive right to distribute EagleDream Health’s powerful tool.
The brain is a marvelously complex structure that keeps us alive and carries within it the quality that makes us unique individuals. This delicate organ can easily go wrong, whether through injury, infection, defect, or disease. One thing that we definitely do understand about the brain is that prolonged neural inflammation causes an array of memory and cognitive disorders often accompanied with neurological diseases, such as Alzheimer's disease, Parkinson's disease (PD), Multiple Sclerosis (MS), and HIV-associated neurocognitive disorders (HAND).

Harris A. Gelbard, M.D., Ph.D., the Director of the Center for Neural Development and Disease, and Professor of Neurology, Pediatrics, and Microbiology & Immunology has been searching for a therapeutic solution for neuroinflammation associated with AIDS for 25 years, with accumulative funding support of $35 million from the NIH. Gelbard, in collaboration with Drs. Stephen Dewhurst and Sanjay Maggirwar from the Department of Microbiology & Immunology, has designed a large portfolio of innovative drug candidates that inhibit the production of Mixed Lineage Kinase enzymes. These enzymes, and in particular MLK3, are understood to trigger the neuroinflammatory process. Gelbard and his team have conducted various pre-clinical screens to validate the concept behind this new approach to treat inflammation.

The lead compounds, in particular URMC-099, are set to be tested in human subjects in 2016. Initial trials will be to determine if this approach is successful in ameliorating Postoperative Cognitive Dysfunction – an irreversible condition caused by neuroinflammation that occurs in elderly patients undergoing a variety of surgical procedures, such as Coronary Artery Bypass Graft surgery.

If successful, these compounds may translate to therapies against MS, PD, HAND, traumatic brain injuries, and other diseases sharing the same underlying etiology. UR Ventures has licensed the patent rights to the novel MLK3 inhibitor compounds to WavoDyne Therapeutics, a biotech startup based in Rochester.

If our brains were simple enough for us to understand them, we'd be so simple that we couldn't.

- Ian Stewart

Applications Are Now Being Accepted for the NSF I-Corps Program

The University of Rochester's I-Corps site is accepting applications for the Spring 2016 cohort. Student, faculty, staff, and alumni teams are encouraged to apply for resources, advice, and modest funding to advance a project toward commercialization. An informational session will be announced soon. Contact Matthew Spielmann for details.

Also in the news:

Clerio Vision was recently featured in the Bio Tuesdays weekly newsletter.

Applications Are Now Being Accepted for the NSF I-Corps Program

The University of Rochester's I-Corps site is accepting applications for the Spring 2016 cohort. Student, faculty, staff, and alumni teams are encouraged to apply for resources, advice, and modest funding to advance a project toward commercialization. An informational session will be announced soon. Contact Matthew Spielmann for details.

Also in the news:

Clerio Vision was recently featured in the Bio Tuesdays weekly newsletter.